Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations

BACKGROUND: Epidermal growth factor receptor (EGFR) is one of the most common oncogenes in non-small cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitor (TKI) and platinum-doublet chemotherapy (PT) are effective regimens in patients with NSCLC harbouring EGFR mutations. Among these patients, pr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:ESMO Open
Main Authors: Shinno, Yuki, Goto, Yasushi, Watanabe, Sho, Sato, Jun, Morita, Ryo, Matsumoto, Yuji, Murakami, Shuji, Kanda, Shintaro, Horinouchi, Hidehito, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2018
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6267457/
https://ncbi.nlm.nih.gov/pubmed/30559979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000399
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares